Your browser doesn't support javascript.
loading
Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences.
Oude Rengerink, Katrien; Kalkman, Shona; Collier, Susan; Ciaglia, Antonio; Worsley, Sally D; Lightbourne, Alison; Eckert, Laurent; Groenwold, Rolf H H; Grobbee, Diederick E; Irving, Elaine A.
Afiliação
  • Oude Rengerink K; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands. Electronic address: k.ouderengerink-2@umcutrecht.nl.
  • Kalkman S; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands.
  • Collier S; RD Respiratory Fibrosis DPU Clinical Development Pharma Research and Development GSK Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex UB11 1BT, UK.
  • Ciaglia A; International Alliance of Patients' Organizations, 49-51 East Road, London N1 6AH, UK.
  • Worsley SD; Real World Study Delivery, GSK Research & Development, Gunnels Wood Rd, Stevenage SG1 2NY, UK.
  • Lightbourne A; International Alliance of Patients' Organizations, 49-51 East Road, London N1 6AH, UK.
  • Eckert L; Health Economics and Outcome Research, Sanofi Global Maket Access Center of Excellence, Chilly-Mazarin, France.
  • Groenwold RHH; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands.
  • Grobbee DE; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands; Julius Clinical, Broederplein 41-43, Zeist 3703 CD, The Netherlands.
  • Irving EA; Real World Study Delivery, GSK Research & Development, Gunnels Wood Rd, Stevenage SG1 2NY, UK.
J Clin Epidemiol ; 89: 173-180, 2017 Sep.
Article em En | MEDLINE | ID: mdl-28502808
ABSTRACT
This paper addresses challenges of identifying, enrolling, and retaining participants in a trial conducted within a routine care setting. All patients who are potential candidates for the treatments in routine clinical practice should be considered eligible for a pragmatic trial. To ensure generalizability, the recruited sample should have a similar distribution of the treatment effect modifiers as the target population. In practice, this can be best achieved by including-within the selected sites-all patients without further selection. If relevant heterogeneity between subgroups is expected, increasing the relative proportion of the subgroup of patients in the heterogeneous trial could be considered (oversampling) or a separate trial in this subgroup can be planned. Selection will nevertheless occur. Low enrollment and loss to follow-up can introduce selection and can jeopardize validity as well as generalizability. Pragmatic trials are conducted in clinical practice rather than in a dedicated research setting, which could reduce recruitment rates. However, if a trial poses a minimal burden to the physician and the patient and routine clinical practice is maximally adhered to, the participation rate may be high and loss to follow-up will not be a specific problem for pragmatic trials.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Seleção de Pacientes / Ensaios Clínicos Pragmáticos como Assunto Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: J Clin Epidemiol Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Seleção de Pacientes / Ensaios Clínicos Pragmáticos como Assunto Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: J Clin Epidemiol Ano de publicação: 2017 Tipo de documento: Article